Dossier assessment
Melphalan flufenamide (multiple myeloma) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Melphalan flufenamide (multiple myeloma) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Melphalan flufenamide (multiple myeloma) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
adults with multiple myeloma who have received at least three prior therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression during or after the last therapy; for patients with prior autologous stem cell transplantation, the time to progression after transplantation should be at least 3 years
added benefit not proven
Project details
- Project no.
- A22-104
- Commission
- Commission awarded on 04.10.2022 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.